

Thomas A Ollila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7230007/publications.pdf>

Version: 2024-02-01

38
papers

438
citations

1040056

9
h-index

794594

19
g-index

38
all docs

38
docs citations

38
times ranked

657
citing authors

#	ARTICLE	IF	CITATIONS
1	Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. <i>Current Treatment Options in Oncology</i> , 2018, 19, 38.	3.0	92
2	Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. <i>JAMA Oncology</i> , 2021, 7, 1714.	7.1	63
3	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
4	<p>Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1085-1094.	2.0	48
5	Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1120-1124.	1.4	34
6	Seroconversion and outcomes after initial and booster <scp>COVID</scp>-19 vaccination in adults with hematologic malignancies. <i>Cancer</i> , 2022, 128, 3319-3329.	4.1	27
7	Time to treatment is an independent prognostic factor in aggressive non-â€Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2018, 181, 495-504.	2.5	21
8	Detection of clonotypic DNA in the cerebrospinal fluid as a marker of-âcentral nervous system invasion in lymphoma. <i>Blood Advances</i> , 2021, 5, 5525-5535.	5.2	18
9	Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. <i>Leukemia</i> , 2020, 34, 2794-2797.	7.2	10
10	Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2019, 60, 3426-3433.	1.3	8
11	Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary. <i>Oncologist</i> , 2020, 25, 555-559.	3.7	7
12	Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 3935-3952.	1.9	7
13	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	1.4	7
14	Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 204-209.	0.4	6
15	Radiation therapy in primary testicular lymphoma: does practice match the standard of care?. <i>Leukemia and Lymphoma</i> , 2019, 60, 523-526.	1.3	6
16	Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2019, 134, 2824-2824.	1.4	6
17	Analysis of Hematology and Oncology Fellowship Website Content and Diversity Representation. <i>JCO Oncology Practice</i> , 2022, , OP2100623.	2.9	4
18	Embolization of Inferior Vena Cava Filter Tyne and Right Ventricular Perforation: A Cardiac Missile. <i>Annals of Thoracic Surgery</i> , 2016, 102, e515-e516.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Acanthocytosis causing chronic hemolysis in a patient with advanced cirrhosis. <i>Blood</i> , 2019, 133, 1518-1518.	1.4	3
20	The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival. <i>Blood</i> , 2015, 126, 4974-4974.	1.4	3
21	Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study. <i>Oncologist</i> , 2022, 27, 532-e542.	3.7	3
22	Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3511-3511.	1.4	2
23	<i>CDKN2A</i> Deletions Define an Unfavorable Subgroup within the <i>MYD88/CD79B</i> (MCD) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) and Are Mutually Exclusive with <i>TP53</i> mutations. <i>Blood</i> , 2021, 138, 2392-2392.	1.4	2
24	RITUXIMAB ALONE (R) VERSUS RITUXIMAB PLUS BENDAMUSTINE (BR) FOR SPLENIC (SMZL) AND NODAL MARGINAL ZONE LYMPHOMA (NMZL). <i>Hematological Oncology</i> , 2019, 37, 225-226.	1.7	1
25	Navigating Roadblocks as an Early Career Attending – Literally. <i>Oncologist</i> , 2020, 25, 995-996.	3.7	1
26	Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia. <i>Blood</i> , 2018, 132, 2442-2442.	1.4	1
27	BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4460-4460.	1.4	1
28	Radiation therapy in primary testicular lymphoma (PTL): Does practice match the standard of care?. <i>Journal of Clinical Oncology</i> , 2018, 36, 7544-7544.	1.6	1
29	Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. <i>Blood</i> , 2019, 134, 2800-2800.	1.4	1
30	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	1.4	1
31	Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study. <i>Blood</i> , 2020, 136, 15-16.	1.4	1
32	Lymph node ratio, adjuvant chemotherapy and survival in resected non-small cell lung cancer and pN1 disease: A Brown University experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18529-e18529.	1.6	0
33	Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era. <i>Blood</i> , 2016, 128, 1994-1994.	1.4	0
34	Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 2913-2913.	1.4	0
35	Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study. <i>Blood</i> , 2019, 134, 3477-3477.	1.4	0
36	Molecular predictors of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20082-e20082.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Abstract PO-27: Clonotypic cell-free DNA (cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas. , 2020, , .		0
38	Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record. Rhode Island Medical Journal (2013), 2020, 103, 78-83.	0.2	0